Search
Livmoniplimab
go.drugbank.com/drugs/DB18939InvestigationalLivmoniplimab is under investigation in clinical trial NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination
Evixapodlin
go.drugbank.com/drugs/DB21520InvestigationalEvixapodlin is under investigation in clinical trial NCT04049617 (Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced
Pateclizumab
go.drugbank.com/drugs/DB14997InvestigationalPateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared
EGT-301
go.drugbank.com/drugs/DB17649ExperimentalIt consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome
Zonampanel anhydrous
go.drugbank.com/drugs/DB20448InvestigationalZonampanel anhydrous is under investigation in clinical trial NCT00044070 (A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients).
Risovalisib
go.drugbank.com/drugs/DB21474InvestigationalRisovalisib is under investigation in clinical trial NCT05043922 (A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma).
AS-8112
go.drugbank.com/drugs/DB09207ExperimentalIt has been shown to exert potent antiemetic effects in animal studies and has been investigated for potential medical use.
Pentaglobin
go.drugbank.com/drugs/DB15865Investigational[A220173] It is comprised of [immunoglobulin G (IgG)](https://www.drugbank.ca/drugs/DB00028) and immunoglobulin A (IgA) while also being enriched by immunoglobulin M (IgM).[L16353]
TAK-428
go.drugbank.com/drugs/DB05499ExperimentalIt is based on the novel concept that peripheral nervous tissue that was damaged by diabetes can be repaired and regenerated by stimulating an increase in neurotrophic factors.
TBC-3711
go.drugbank.com/drugs/DB05407InvestigationalTBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.